Notice of NINDS Participation in PAR-14-092 "Bioengineering Research Partnerships (BRP) (R01)"

Notice Number: NOT-NS-14-014

Key Dates
Release Date: March 3, 2014

Related Announcements
PAR-14-092

Issued by
National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this Notice is to inform applicants that the National Institute of Neurological Disorders and Stroke (NINDS) has joined the funding opportunity announcement PAR-14-092, entitled “Bioengineering Research Partnerships (BRP) (R01)”, effective immediately.

The following sections of PAR-14-092 have been updated to reflect the participation of NINDS in this FOA.

Part 1. Overview Information

Components of Participating Organizations
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Human Genome Research Institute (NHGRI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Neurological Disorders and Stroke (NINDS)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.286, 93.172, 93.865, 93.399, 93.396, 93.395, 93.394, 93.393, 93.273, 93.867, 93.279, 93.113, 93.866, 93.853

Part 2. Section I. Funding Opportunity Description 

Scope of the Program

For applications relevant to the mission of the National Institute of Neurological Disorders and Stroke (NINDS): NINDS will not support first in human demonstrations, early Feasibility studies or definitive clinical trials of therapeutics through the BRP mechanism (Phase I, Phase II, and Phase III, Feasibility/Pivotal trials), but does support these efforts through other mechanisms (see http://www.ninds.nih.gov/research/clinical_research/ for details).  Pre-clinical efforts leading directly to an FDA submission to obtain an Investigational Device Exemption (IDE) are also supported through other mechanisms (see http://www.ninds.nih.gov/funding/funding_announcements/Funding-Bins-Translational-Research.htm for details).  Investigators should contact NINDS Program Staff to identify the appropriate mechanism for such clinical efforts.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kip Ludwig, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1447
Email: Kip.Ludwig@nih.gov

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.